ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
November 20, 2012

ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C.

Read More
November 15, 2012

ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C.

Read More
October 08, 2012

Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing

Read More
September 07, 2012

ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012

Read More
July 13, 2012

ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012

Read More
July 03, 2012

ImmuPharma PLC Appoints Cenkos Securities as Joint Broker

Read More
March 27, 2012

PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2011

Read More
February 29, 2012

ImmuPharma PLC Appoints Head of Investor Relations

Read More
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved